2 news items
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia
LRMR
30 May 24
in the START pilot program. This selection highlights the commitment of the FDA to augment currently available formal meeting communications with more rapid, ad
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
LRMR
9 May 24
Commitments
- Prev
- 1
- Next